Programmed death 1 (PD-1) serum level and gene expression in recent onset systemic lupus erythematosus patients
Programmed death 1 (PD-1) serum level and gene expression in recent onset systemic lupus erythematosus patients
复制标题
DOI：
10.1016/j.ejr.2021.02.005
复制
发表时间：
2021-03-10
影响因子：
0.9
通讯作者：
Gharbia, Ola M.
中科院分区：
文献类型：
--
作者：
Bassiouni, Sherine A.;Abdeen, Hanaa M.;Gharbia, Ola M.
工作目标：为探讨新近发病的系统性红斑狼疮（SLE）患者血清中蛋白程序性死亡1（PD-1）水平及其基因表达与疾病活动性的关系，研究对象和方法：本研究包括80例新近诊断的SLE患者和80例健康对照者。评估SLE疾病活动指数（SLEDAI）。采用酶联免疫吸附试验（ELISA）检测血清可溶性蛋白（sPD-1）水平，采用真实的时间-聚合酶链反应（RT-PCR）检测sPD-1基因表达水平。患者的sPD-1和PD-1基因表达水平（倍数）（1280.6 +/- 1448.1 pg/ml和0.3 +/- 0.06倍）显著高于对照组（109.1 +/- 11.9 pg/ml和0.03 +/- 0.008倍）（p < 0.001）。sPD-1与血尿、脓尿、发热和C3水平显著相关（分别为p = 0.01、p = 0.001、p = 0.02和p = 0.03），PD-1基因表达与精神病和发热显著相关（p = 0.03、p = 0.014）。SLEDAI与PD-1基因表达或sPD-1水平无显著相关性（分别为p = 0.1，p = 0.23）。sPD-1和PD-1基因表达水平与自身抗体无明显相关性。结论：PD-1基因表达和血清sPD-1水平在初发SLE患者中明显升高，可能参与了疾病的发病过程，但与疾病活动性无关。这种生物标志物可能有希望通过靶向PD-1途径开发一种新的狼疮免疫疗法。(C)2021年埃及风湿病学会。Elsevier B. V.提供的出版服务。
Aim of the work: To investigate the potential association of protein programmed death 1 (PD-1) serum level and its gene expression inrecent onset systemic lupus erythematosus (SLE) patients and study its association with the disease activity.Patients and methods: The study included 80 recently diagnosed SLE patients and 80 healthy controls. SLE disease activity index (SLEDAI) was assessed. The serum level of soluble (sPD-1) was assessed by enzyme linked immunosorbent assay (ELISA) and its gene expression level was evaluated by real time-polymerase chain reaction (RT-PCR).Results: They were 68 females and 12 males (F: M 5.7:1) with age 30.8 +/- 8.7 years and disease duration of 3.2 +/- 1.7 months. The sPD-1 and PD-1 gene expression level (folds) were significantly elevated in patients (1280.6 +/- 1448.1 pg/ml and 0.3 +/- 0.06 folds) than controls (109.1 +/- 11.9 pg/ml and 0.03 +/- 0.008 folds) (p < 0.001). A significant correlation was found between sPD-1 and hematuria, pyuria, fever and C3 level (p = 0.01, p = 0.001, p = 0.02, and p = 0.03 respectively), and between PD-1gene expression and psychosis and fever (p = 0.03, p = 0.014). No significant correlation was found between SLEDAI and PD-1 gene expression or sPD-1 level (p = 0.1, p = 0.23 respectively). No significant correlation was found between sPD-1 and PD-1 gene expression levels and the autoantibodies.Conclusion: PD-1 gene expression as well as the serum level of sPD-1 are elevated significantly in recent onset SLE patients denoting that they may have a role in the pathogenesis of the disease while there was no relation to the disease activity. This biomarker may be potentially promising for the development of a novel lupus immunotherapy by targeting the PD-1 pathway. (C) 2021 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V.